{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:25:13Z","timestamp":1787869513679,"version":"build-2784847793"},"reference-count":16,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Australas Psychiatry"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Lurasidone is a new serotonin\u2013dopamine antagonist atypical antipsychotic which also appears to be effective in bipolar depression. This paper will briefly review the evidence concerning lurasidone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Lurasidone is an antagonist at dopamine D\n                      <jats:sub>2<\/jats:sub>\n                      , serotonin 5-HT\n                      <jats:sub>2<\/jats:sub>\n                      and 5-HT\n                      <jats:sub>7<\/jats:sub>\n                      , and partial agonist at 5HT\n                      <jats:sub>1a<\/jats:sub>\n                      receptors; it has no anticholinergic or antihistaminic activity. Rapidly absorbed, it has a half-life of 18 \u00b1 7 hours, will reach steady state in five days and is taken at night with food (absorption is halved on an empty stomach). It is hepatically metabolised with some potential for interactions. Lurasidone is an effective antipsychotic in acute schizophrenia, and non-inferior to quetiapine but not risperidone in 12-month studies. Lurasidone may cause mild sedation, nausea, agitation, insomnia and akathisia (especially at initiation). Risks for weight gain, hyperprolactinaemia and QT\n                      <jats:sub>c<\/jats:sub>\n                      prolongation are low. Lurasidone has demonstrated antidepressant efficacy both as monotherapy and in addition to lithium or valproate in bipolar depression, of a comparable degree to that seen with the combination of olanzapine and fluoxetine. Lurasidone appears to be a \u201cmetabolically-friendly\u201d antipsychotic for schizophrenia where weight gain and hyperprolactinaemia are of concern, and may also prove useful in bipolar depression (although not approved for this condition in Australia).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1039856216641309","type":"journal-article","created":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T22:24:21Z","timestamp":1459549461000},"page":"289-291","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Lurasidone: an antipsychotic with antidepressant effects in bipolar depression?"],"prefix":"10.1177","volume":"24","author":[{"given":"Nicholas A","family":"Keks","sequence":"first","affiliation":[{"name":"Professor, Monash University, Melbourne, VIC, and; Director, Centre of Mental Health Education and Research at Delmont Private Hospital, Glen Iris, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Hope","sequence":"additional","affiliation":[{"name":"Psychiatrist, Eastern Health, Senior Lecturer, Monash University, Melbourne, VIC, and; Deputy Director, Centre of Mental Health Education and Research at Delmont Private Hospital, Glen Iris, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Castle","sequence":"additional","affiliation":[{"name":"Chair of Psychiatry, St Vincent\u2019s Hospital, University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,6,1]]},"reference":[{"key":"bibr1-1039856216641309","first-page":"361","volume-title":"Essentials of clinical psychopharmacology","author":"Harvey PD","year":"2013","edition":"3"},{"key":"bibr2-1039856216641309","unstructured":"Servier Laboratories. Product information. Latuda (lurasidone hydrochloride). Hawthorn, Australia: Servier Laboratories Pty Ltd, 7 September 2015."},{"key":"bibr3-1039856216641309","unstructured":"Therapeutic Goods Administration. Australian public assessment report for lurasidone hydrochloride. Woden, ACT: Commonwealth of Australia, 2014."},{"key":"bibr4-1039856216641309","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10060907"},{"key":"bibr5-1039856216641309","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.03.013"},{"key":"bibr6-1039856216641309","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32835281ef"},{"key":"bibr7-1039856216641309","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"bibr8-1039856216641309","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.01.004"},{"key":"bibr9-1039856216641309","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2013.08.003"},{"key":"bibr10-1039856216641309","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S68417"},{"key":"bibr11-1039856216641309","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13070984"},{"key":"bibr12-1039856216641309","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13070985"},{"key":"bibr13-1039856216641309","volume-title":"Stahl\u2019s essential psychopharmacology. Prescribers guide","author":"Stahl SM","year":"2014","edition":"5"},{"key":"bibr14-1039856216641309","first-page":"1199","volume":"65","author":"Calabrese JR","year":"2004","journal-title":"J C Psychiatry"},{"key":"bibr15-1039856216641309","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12343"},{"key":"bibr16-1039856216641309","first-page":"2143","volume":"11","author":"Franklin R","year":"2015","journal-title":"Neuropsychiatr Dis and Treat"}],"container-title":["Australasian Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1039856216641309","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1039856216641309","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1039856216641309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:48:12Z","timestamp":1777376892000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1039856216641309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1177\/1039856216641309"],"URL":"https:\/\/doi.org\/10.1177\/1039856216641309","relation":{},"ISSN":["1039-8562","1440-1665"],"issn-type":[{"value":"1039-8562","type":"print"},{"value":"1440-1665","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}